Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
-4.31%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$43.7B
AUM Growth
+$158M
(+0.36%)
Cap. Flow
+$1.17B
Cap. Flow
% of AUM
2.67%
Top 10 Holdings %
Top 10 Hldgs %
11.64%
Holding
4,109
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| 1 |
Hewlett Packard
HPE
|
$488M |
| 2 |
Halliburton
HAL
|
$458M |
| 3 |
Archer Daniels Midland
ADM
|
$456M |
| 4 |
Gen Digital
GEN
|
$413M |
| 5 |
WESCO International
WCC
|
$251M |
Top Sells
| 1 |
Vistra
VST
|
$614M |
| 2 |
Exxon Mobil
XOM
|
$498M |
| 3 |
Chevron
CVX
|
$435M |
| 4 |
Occidental Petroleum
OXY
|
$432M |
| 5 |
Cisco
CSCO
|
$411M |
Sector Composition
| 1 | Consumer Discretionary | 17.28% |
| 2 | Technology | 17.14% |
| 3 | Energy | 14.05% |
| 4 | Industrials | 10.98% |
| 5 | Healthcare | 9.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Booz Allen Hamilton
BAH
$12.7B
| $27.1K | ﹤0.01% |
176
+19
| +12% | +$2.92K |
|
1302
Arcellx
ACLX
$3.96B
| $26.9K | ﹤0.01% |
488
-105
| -18% | -$5.8K |
|
1303
Intellia Therapeutics
NTLA
$1.27B
| $26.5K | ﹤0.01% |
1,186
-241
| -17% | -$5.39K |
|
|
SWI
1304
DELISTED
SolarWinds Corporation Common Stock
SWI
| $26.1K | ﹤0.01% |
2,162
-502
| -19% | -$6.05K |
|
|
NNDM
1305
Nano Dimension
NNDM
$289M
| $26K | ﹤0.01% |
11,815
-1,936
| -14% | -$4.26K |
|
1306
JFrog
FROG
$5.7B
| $25.9K | ﹤0.01% |
690
-30
| -4% | -$1.13K |
|
1307
Amicus Therapeutics
FOLD
$2.49B
| $25.8K | ﹤0.01% |
2,597
-871
| -25% | -$8.64K |
|
1308
Avidity Biosciences
RNA
$6.44B
| $25.4K | ﹤0.01% |
622
-309
| -33% | -$12.6K |
|
|
FARO
1309
DELISTED
Faro Technologies
FARO
| $25.2K | ﹤0.01% |
1,577
+468
| +42% | +$7.49K |
|
1310
Celldex Therapeutics
CLDX
$1.52B
| $25.2K | ﹤0.01% |
680
-210
| -24% | -$7.77K |
|
1311
Vera Therapeutics
VERA
$1.44B
| $25.1K | ﹤0.01% |
693
-117
| -14% | -$4.23K |
|
1312
AvePoint
AVPT
$3.45B
| $24.8K | ﹤0.01% |
+2,382
| New | +$24.8K |
|
1313
Semtech
SMTC
$5.27B
| $24.8K | ﹤0.01% |
829
-199
| -19% | -$5.95K |
|
1314
IDEAYA Biosciences
IDYA
$2.29B
| $24K | ﹤0.01% |
683
-252
| -27% | -$8.85K |
|
1315
Geron
GERN
$868M
| $23.3K | ﹤0.01% |
5,503
-5,720
| -51% | -$24.3K |
|
1316
Extreme Networks
EXTR
$2.93B
| $22.5K | ﹤0.01% |
1,672
-6,609,631
| -100% | -$88.9M |
|
1317
Beam Therapeutics
BEAM
$1.98B
| $22K | ﹤0.01% |
940
-194
| -17% | -$4.55K |
|
1318
MaxLinear
MXL
$1.36B
| $21.5K | ﹤0.01% |
1,069
-238
| -18% | -$4.79K |
|
1319
Immunovant
IMVT
$2.91B
| $21.1K | ﹤0.01% |
800
-543
| -40% | -$14.3K |
|
1320
Syndax Pharmaceuticals
SNDX
$1.45B
| $20.8K | ﹤0.01% |
1,012
-722
| -42% | -$14.8K |
|
1321
Denali Therapeutics
DNLI
$2.22B
| $20K | ﹤0.01% |
862
-1,163
| -57% | -$27K |
|
|
ECC
1322
Eagle Point Credit Co
ECC
$979M
| – | – |
0
| – | -$19.3K |
|
1323
Novavax
NVAX
$1.25B
| $18.9K | ﹤0.01% |
1,489
-6,339
| -81% | -$80.3K |
|
1324
Agios Pharmaceuticals
AGIO
$2.12B
| $18.8K | ﹤0.01% |
437
-594
| -58% | -$25.6K |
|
1325
Janux Therapeutics
JANX
$1.44B
| $18.4K | ﹤0.01% |
+439
| New | +$18.4K |
|